ALZAMEND NEURO, INC. Investing Cash Flow
ALZAMEND NEURO, INC. (ALZN) reported Investing Cash Flow of -$300.00 thousand for the 12-month period ending 2025-04-30, per its 10-K filed 2026-07-22.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-07-22
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for the quarter ending 2025-04-30 was -$210.00K.
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for the quarter ending 2025-01-31 was $0.00.
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for the quarter ending 2024-10-31 was $0.00.
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for the quarter ending 2024-07-31 was -$90.00K.
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$300.00K.
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for fiscal 2024 was -$147.24K.
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$106.46K, a 205.49% decline from fiscal 2021.
- ALZAMEND NEURO, INC. net cash provided by (used in) investing activities for fiscal 2021 was $100.92K, a 3.89% decline from fiscal 2020.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2025-04-30 | -$210.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | -$210.00K derived: sum of 2 quarters · filed 2026-07-22 | -$210.00K derived: sum of 3 quarters · filed 2026-07-22 | -$300.00K 10-K · filed 2026-07-22 |
| 2025-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $0.00 derived: sum of 2 quarters · filed 2026-03-11 | -$90.00K 10-Q · filed 2026-03-11 | -$90.00K derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | -$90.00K 10-Q · filed 2025-12-09 | -$90.00K derived: sum of 3 quarters · filed 2025-12-09 | -$90.00K derived: sum of 4 quarters · filed 2025-12-09 |
| 2024-07-31 | -$90.00K 10-Q · filed 2025-09-10 | -$90.00K derived: sum of 2 quarters · filed 2025-09-10 | -$90.00K derived: sum of 3 quarters · filed 2025-09-10 | -$90.00K derived: sum of 4 quarters · filed 2025-09-10 |
| 2024-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-22 | $0.00 derived: sum of 2 quarters · filed 2025-07-22 | $0.00 derived: sum of 3 quarters · filed 2025-07-22 | -$147.24K 10-K · filed 2025-07-22 |
| 2024-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-10 | $0.00 derived: sum of 2 quarters · filed 2025-03-10 | -$147.24K 10-Q · filed 2025-03-10 | |
| 2023-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-11 | -$147.24K 10-Q · filed 2024-12-11 | ||
| 2023-07-31 | -$147.24K 10-Q · filed 2024-09-11 | |||
| 2022-04-30 | -$106.46K 10-K · filed 2023-07-27 | |||
| 2021-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | $0.00 derived: sum of 2 quarters · filed 2022-07-19 | $0.00 derived: sum of 3 quarters · filed 2022-07-19 | $100.92K 10-K · filed 2022-07-19 |
| 2021-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | $0.00 derived: sum of 2 quarters · filed 2022-03-15 | $100.92K 10-Q · filed 2022-03-15 | |
| 2020-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | $100.92K 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | $100.92K 10-Q · filed 2021-09-13 | |||
| 2020-04-30 | $105.00K 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |